Vernalis (R&D) Ltd.
http://www.vernalis.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vernalis (R&D) Ltd.
M&A Activity During Q2 Declined In Volume And Valuation
Following a pair of $10bn+ deals in Q4 2023 and a $16.5bn takeout in Q1, the second quarter saw no acquisition priced as high as $5bn, Evaluate notes. Aggregate deal volume and values dropped from Q1.
Asahi Kasei Furthers Its US, Health Care Growth With $1.1bn Calliditas Buy
Asahi Kasei established a US presence and expertise in renal disease when it bought Veloxis in 2020 and will expand in both areas with Calliditas’s Tarpeyo for immunoglobulin A nephropathy (IgAN).
Novartis Aims To Dominate Rare Renal Disorders
Fabhalta and atrasentan are odds-on for approval in C3 glomerulopathy and IgA nephropathy, respectively, but commercial success might be harder to come by.
First-To-Market Calliditas Picking Up Speed In IgA Nephropathy
A few hiccups aside, Tarpeyo is on track in the US, but major competition from Novartis is just round the corner.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Cita NeuroPharmaceuticals
- Vernalis Group plc
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice